New research reinforces life-saving benefits of puberty blockers for trans youth

A recent study has added to the compelling body of evidence supporting the critical role of puberty blockers in safeguarding the mental health of transgender youth. Research set to be featured in the February edition of the Journal of Pediatrics confirms that trans adolescents experience significant decreases in suicidal ideation during gender-affirming care.

Conducted by pediatricians from Nevada, Texas, and Missouri, the study analyzed the mental wellbeing of 432 participants, aged 12 to 20, before and after they began medically appropriate treatments, including puberty blockers and hormone replacement therapy (HRT).

Utilizing the Ask Suicide-Screening Questions (ASQ) toolkit, an internationally recognized method for assessing suicidality, the researchers observed marked improvements in the mental health of patients across the board. Notably, the study reported a substantial decline in suicidality over time, with reductions continuing as treatment progressed.

The findings indicated that these positive outcomes were consistent across various factors, including gender identity, length of treatment, and age at the initiation of therapy. This reinforces not only the effectiveness of gender-affirming care in enhancing the wellbeing of trans individuals but also suggests that the benefits in reducing suicidal tendencies remain robust as patients mature.

The researchers advocate for further investigation with a larger sample size and extended follow-up to validate the effectiveness of gender-affirming care’s mental health interventions.

Despite mounting evidence supporting the positive impact of gender-affirming care, many politicians continue to push for bans on puberty blockers. Studies conducted worldwide consistently reveal that gender-affirming care is overwhelmingly beneficial for trans individuals, particularly adolescents. For example, an October 2024 study indicated that 97% of trans youth under 18 expressed high satisfaction with their gender-affirming treatments. Another study from March reported that of 548 patients who received transgender healthcare, only two expressed regret over their decisions.

Furthermore, a May 2024 paper detailed low regret rates for gender-affirming treatments, noting that individuals are more likely to regret procedures such as knee surgeries, breast augmentations, and even parenthood than transitioning-related medical care.

Despite this extensive array of evidence demonstrating the life-saving potential of gender-affirming care, anti-trans lawmakers frequently argue against access to clinically approved medical treatments for trans youth.

Currently, at least 27 states in the U.S. impose restrictions on gender-affirming care, effectively denying over 40% of the country’s transgender youth access to necessary treatments. Similarly, puberty blockers are prohibited for trans youth in the UK, even as they remain available to their cisgender counterparts.

The Trevor Project, a prominent LGBTQ+ suicide prevention organization, has expressed concerns that these legislative bans have severe negative consequences for the mental health of trans youth, who are already at a heightened risk for suicidal feelings.

Research from Dr. Natacha Kennedy at the University of London critically examines recent legislative efforts, particularly Wes Streeting’s ban on puberty blockers, which she asserts is “significantly, extensively, and relentlessly harming trans children and young people.” She highlighted accounts from parents whose trans children, once described as “happy and well-adjusted,” have sadly resorted to self-harm due to the barriers in accessing appropriate care.